UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000024322
Receipt No. R000028013
Scientific Title Prospective study of safety and usefulness of transcatheter arterial chemo- embolization by miriplatin and lipiodol for thoracic malignant tumors
Date of disclosure of the study information 2016/10/11
Last modified on 2016/10/06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Prospective study of safety and usefulness of transcatheter arterial chemo- embolization by miriplatin and lipiodol for thoracic malignant tumors
Acronym Transcatheter arterial chemo- embolization by miriplatin and lipiodol for thoracic malignant tumors
Scientific Title Prospective study of safety and usefulness of transcatheter arterial chemo- embolization by miriplatin and lipiodol for thoracic malignant tumors
Scientific Title:Acronym Transcatheter arterial chemo- embolization by miriplatin and lipiodol for thoracic malignant tumors
Region
Japan

Condition
Condition Thoracic malignant tumors
Classification by specialty
Pneumology Hematology and clinical oncology Chest surgery
Adult Child
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The purpose is to examine the tumor response rate and safety of arterial infusion of miriplatin and lipiodol for thoracic malignant tumors, which are difficult to treat by surgery, radiationtherapy, and general chemotherapy.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Explanatory
Developmental phase Phase II

Assessment
Primary outcomes Tumor response rate and complications
Key secondary outcomes Local control period and overall survival

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
10 years-old <=
Age-upper limit
100 years-old >
Gender Male and Female
Key inclusion criteria 1. Thoracic malignant tumros which can be treated by transcatheter arterial chemo- embolization.
2. The patients who are difficult to be treated by surgery, radiotherapy, and chemotherapy.
3. The patients who are not expected by transcatheter arterial embolization.
4. The patients who meet all of those condisitons.
Or the operable patients who are judged to be better treated by transcatheter arterial chemo-embolization for decreasing tumors before surgery
Key exclusion criteria 1. The patients without inclusion criteria.
2. The patients with allergy for blood vessel contrast medium.
3. The patients with renal failure.
4. The patients who are judged to be unsuitable by doctors.
Target sample size 30

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Hiroaki Nomori
Organization Kameda Medical Center
Division name Thoracic surgery
Zip code
Address 929 Higashicho, Kamogawa CIty, Chiba
TEL 0470-92-2211
Email hnomori@qk9.so-net.ne.jp

Public contact
Name of contact person
1st name
Middle name
Last name Hiroaki Nomori
Organization Kameda Medical Center
Division name Thoracic surgery
Zip code
Address 929 Higashicho, Kamogawa CIty, Chiba
TEL 0470-92-2211
Homepage URL
Email hnomori@qk9.so-net.ne.jp

Sponsor
Institute Kameda Medical Center
Institute
Department

Funding Source
Organization None of the research fund
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 10 Month 11 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2016 Year 10 Month 06 Day
Date of IRB
Anticipated trial start date
2016 Year 10 Month 11 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information There is no other informations.

Management information
Registered date
2016 Year 10 Month 06 Day
Last modified on
2016 Year 10 Month 06 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028013

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.